-
The cold winter has passed, and the half-year performance of five listed vaccine companies ushered in a "big counterattack"!
Time of Update: 2017-09-20
In the first half of last year, affected by the "vaccine incident", domestic second-class vaccine manufacturers suffered "Waterloo" in performance At that time, the performance of Zhifei biology fell
-
Recent inventory of new drugs in China
Time of Update: 2017-09-19
This paper is organized by heroiv according to the public information Fevipiprant (nvp-qaw039) is a prostaglandin D2 receptor (DP2 / CRTH2) inhibitor It has entered the third phase of clinical practic
-
The top 8 children's pharmaceutical companies have made great achievements in half a year, and the most profitable one is it!
Time of Update: 2017-09-18
Wonderful content since 2015, the favorable policies of children's medicine have been continuous In addition to encouraging research and development, giving priority to evaluation, strengthening hospi
-
Will the market of surgical anesthetics grow by a straight line in the next 10 years?
Time of Update: 2017-09-16
According to the 2017 blue book on the development of China's pharmaceutical market, the sales volume of China's pharmaceutical terminal market in 2016 was 1497.5 billion yuan, up 8.3% year on year, a
-
The best-selling echelon of brain neuroprotective agents: three over 1 billion yuan varieties
Time of Update: 2017-09-15
September 16 is "China Brain Health Day" With the continuous acceleration of the pace of life, some symptoms related to brain health, such as headache, dizziness, neurasthenia, cerebrovascular acciden
-
The leading position of blood products has changed! Why the revenue of the three companies soared in the first half of the year?
Time of Update: 2017-09-14
In 2017, in the new version of the medical insurance catalog, the types and scope of reimbursement for blood products have increased significantly, which will benefit more patients In recent years, th
-
A pharmaceutical company has the patent right of apatini, a heavyweight drug, which was completely exploded by Hengrui!
Time of Update: 2017-09-12
The result of patent infringement case against apatinib, Hengrui's heavyweight new drug, came out: on August 31, 2017, the Patent Reexamination Board decided that the patent right zl201510398190.1 of
-
The growth rate exceeds 20%! Four major varieties lead the tens of billions of antibody drugs market
Time of Update: 2017-09-10
In the new round of drug price negotiation, 36 negotiated drugs are included in the category B scope of the 2017 edition of the national directory of drugs for basic medical insurance, industrial inju
-
"Acid rain" eroded PPI "golden age", look at the "razole" family!
Time of Update: 2017-09-05
According to WHO data, the incidence rate of digestive system is 10% to 12%, and the incidence rate of digestive system in China is 11.2%, which is basically the same as that in many developed countri
-
August CDE: the new anticancer drug niraparib was applied for clinical application, and ibotinib capsule was approved for import
Time of Update: 2017-09-03
Abstract: pyrrolidine maleate of abstract Hengrui medicine is declared to be on the market; gb223 injection and gb235 injection of Jiahe bio start technical review of entering CDE; niraparib capsule (
-
The first three kinds of blood products take 80% of the market! How fast are their growth rates?
Time of Update: 2017-09-01
According to the annual report on the issuance of batches of biological products, in 2016, China issued 3949 batches of vaccines, about 646 million copies; 4025 batches of blood products, about 59.278
-
Huahai Pharmaceutical's PIV patent challenge succeeded, and preparations ushered in the "Golden Era" of export!
Time of Update: 2017-08-30
Recently, Huahai pharmaceutical announced that the 7.5mg anda of paroxetine capsule submitted by Prinston has been approved Paroxetine capsules were developed by noven and listed in the United States
-
Facing the golden age of BPH market under high prevalence: a close look at the performance of four major varieties
Time of Update: 2017-08-29
Male genitourinary system disease is still the ninth leading cause of male death in China According to the official data of 2016 China Statistical Yearbook, the mortality rate of urban male genitourin
-
Hengrui's innovative medicine is breaking out, another 1 billion varieties will be born?
Time of Update: 2017-08-26
Recently, Hengrui pharmaceutical announced that the company's Btk kinase inhibitor shr1459 has obtained the CFDA clinical trial approval and will carry out phase I clinical trial in the near future In
-
Priority evaluation characteristics of domestic drugs, imported drugs and children's drugs from 51 approvals
Time of Update: 2017-08-25
Since the implementation of CFDA priority review and approval system in 2016, Xianda data v3.2 found that there are 55 production approvals related to the priority review and approval policy, includin
-
Growth rate: 268% + new medical insurance! Alisartan, a new Chinese drug, is going to stir up 80 billion hypertension Market
Time of Update: 2017-08-24
According to the 2015 China hypertension rational drug use guidelines, there are 298 million Chinese adults with hypertension At the pass of hypertension, the current situation is that there is still
-
The release of the new version of the guide to rational use of hypertension will give birth to 5 heavyweight varieties!
Time of Update: 2017-08-24
After two years, the revision of the second edition of the guidelines for rational use of hypertension, led by the Expert Committee on rational use of drugs of the national health and Family Planning
-
From 40 billion to 150 billion in seven years, behind the leaping growth of Hengrui's market value
Time of Update: 2017-08-21
Everytime Hengrui's market value leaping growth comes from three breakthroughs: first, the harvest of innovation achievements, the volume of new drugs on the market or the expectation of innovation ac
-
Antibody drug development capability test of local enterprises: Where is the main bottleneck? How competitive is it?
Time of Update: 2017-08-20
In the global scope, with the rapid development of biotechnology, the development direction of the pharmaceutical industry has gradually changed from chemical small molecule drugs to biological drugs
-
In half a year, heavy new drugs appear frequently, and nervous system diseases are frequently used
Time of Update: 2017-08-14
With the deepening of social aging, the incidence rate of neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease is also increasing The market situation of nervous system disea
